ADMA Biologics (NASDAQ:ADMA) is a biopharmaceutical company deeply engaged in the development, manufacturing, and marketing of plasma-derived products for the treatment and prevention of infectious diseases. Their operations focus primarily on immune globulins, a class of medicines vital for people with weakened immune systems. A key aspect of their mission is to improve patient outcomes in immune-compromised and other patient populations across the globe. Through dedicated research and strategic collaborations, ADMA Biologics aims to expand its product portfolio, ensuring access to life-saving therapies for individuals in need. Their objectives center around advancing the quality and safety of plasma-derived therapies, increasing their market presence, and playing a pivotal role in the fight against infectious diseases by bringing innovative solutions to the healthcare sector.